HIF1A and non-small cell lung carcinoma: Clinically, these results point toward a therapeutic rationale for combining bevacizumab and anlotinib in advanced NSCLC, particularly in patient subsets characterized by high HIF-1α expression or resistance to prior VEGF-targeted therapy.